Adding subcutaneous epcoritamab to R-CHOP significantly improves PFS in newly diagnosed DLBCL, potentially reshaping frontline therapy with a tolerable safety profile.
|Articles|December 8, 2014
Brentuximab Vedotin in Combination With Bendamustine for Patients With Hodgkin Lymphoma
Author(s)Ann S. LaCasce, MD
Ann S. LaCasce, MD, discusses the combination of brentuximab vedotin and bendamustine for the treatment of patients with Hodgkin lymphoma.
Advertisement
Clinical Pearls
Ann S. LaCasce, MD, assistant professor of medicine, Harvard Medical School, lymphoma program, Dana-Farber Cancer Institute, discusses the combination of brentuximab vedotin and bendamustine for the treatment of patients with Hodgkin lymphoma.
- The study analyzed 53 patients with Hodgkin lymphoma who were in first relapse or had primary refractory disease after initial therapy.
- Patients were treated with brentuximab vedotin in combination with bendamustine.
- The overall response rate was 96%.
- 83% of patients achieved a complete remission.
- Some unexpected infusion-related toxicity was observed.
<<<
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.
Resubmitted FDA filing advances off-the-shelf EBV-specific T-cell therapy tab-cel for relapsed EBV+ PTLD after transplant, with longer follow-up.
Advertisement
Advertisement